Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
